Bronchiectasis Drugs Market Future Outlook, COVID-19 Impact Analysis, Forecast – 2031

The global bronchiectasis drugs market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). Some pivotal factors that are driving the market growth include the high presence of bronchiectasis among the public and the improved infrastructure facilities in the healthcare and medical sector. Another key factor anticipate to drive the market growth include the constant R&D in the field of bronchiectasis drugs coupled with the rising competition among established drug makers.

Get Free Sample link @ https://www.omrglobal.com/request-sample/bronchiectasis-drugs-market

Under the global bronchiectasis drugs market, the major types of drugs available include antibiotics and expectorants. Among these two, antibiotics have the greater demand and are anticipated to continue to stay ahead of the expectorant segment in the future years. An increase in the number of respiratory diseases has been driving the antibiotics demand. In addition, the low cost and easy availability of these antibiotics have led to the demand substantially as well.

Some key players operating in the market include Endo International Plc, GlaxoSmithKline Plc,., Reckitt and Benckiser Group Plc, among others. These players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in April 2014, Bayer HealthCare announced that the US Food and Drug Administration’s (FDA) Office of Orphan Products Development has granted orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis (NCFB). Such approvals for the novel forms of drugs from the FDA for the treatment of bronchiectasis are further anticipated to drive the market growth during the forecast period.

Full report of Bronchiectasis Drugs Market available @ https://www.omrglobal.com/industry-reports/bronchiectasis-drugs-market

Market Coverage

  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape: Endo International Plc, GlaxoSmithKline Plc,., Reckitt and Benckiser Group Plc, among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o             Recovery Timeline

o             Deviation from pre-COVID forecast

o             Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Bronchiectasis Drugs Market by Segmentation

By Product

  • Antibiotics
  • Expectorants
  • Other Drugs

Reasons to Buying From us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

 

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/bronchiectasis-drugs-market

 

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.